White Paper | 2019 Annual Meeting | Characterizing the Use of External Controls for Augmenting Randomized Control Arms and Confirming Benefit | November 8, 2019 Share
White Paper | 8th Annual Blueprint for Breakthrough – Validating Real-World Endpoints for an Evolving Regulatory Landscape | September 18, 2019 Share
White Paper | Opportunities for Combination Drug Development: Data Sources and Innovative Strategies to Assess Contribution of Components | July 17, 2019 Share
White Paper | 2018 Annual Meeting – Panel 3 | Real-Time Oncology Review and the Assessment Aid: Increasing Review Efficiency Through Standardization and Earlier Data Access | November 16, 2018 Share
White Paper | 2018 Annual Meeting – Panel 2 | Exploring the Use of Circulating Tumor DNA as a Monitoring Tool for Drug Development | November 16, 2018 Share
White Paper | 2018 Annual Meeting – Panel 1 | Exploring Whether A Synthetic Control Arm can be Derived from Historical Clinical Trials that Match Baseline Characteristics and Overall Survival Outcome of a Randomized Control Arm | November 16, 2018 Share
White Paper | Broadening the Definition of Tolerability in Cancer Clinical Trials to Better Measure the Patient Experience | October 24, 2018 Share
White Paper | Friends-Alexandria 7th Annual Blueprint for Breakthrough Forum | Research and Reimbursement in the Age of Precision Medicine | September 14, 2018 Share
